Article

NOW AVAILABLE: A Special Report on Diabetes Innovation 2012

Conference|Diabetes Innovation

To act as a catalyst for ideas, partnerships, and collaboration among all stakeholders to provoke thought, innovation, and action to address the cost, productivity, and quality-of-life impact of diabetes, obesity, and related conditions and comorbidities on our society, Joslin Diabetes Center convened Diabetes Innovation for the first time in 2012. Highlights from Diabetes Innovation, which took place on September 23-25 2012, in Arlington, Virginia, are available in a special report published by The American Journal of Managed Care.

This publication has been supported by funding from Sanofi.

To act as a catalyst for ideas, partnerships, and collaboration among all stakeholders to provoke thought, innovation, and action to address the cost, productivity, and quality-of-life impact of diabetes, obesity, and related conditions and comorbidities on our society, Joslin Diabetes Center convened Diabetes Innovation for the first time in 2012. Highlights from Diabetes Innovation, which took place on September 23-25 2012, in Arlington, Virginia, are available in a special report published by The American Journal of Managed Care.

This publication captures key learning points from several of the interactive panels and spotlight forums that took place at Joslin Diabetes Center’s first annual Diabetes Innovation.

To access the publication, please click here or the image below.

Diabetes Innovation 2012
Related Videos
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
ASCO 2025
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Samir Shah, MD, MMM, FACR
Dr Brian Slomovitz
Reynold Panettieri, Jr, MD
Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre
Jill Feldman, patient, cofounder and president, EGFR Resisters
Reynold Panettieri, Jr, MD
Related Content
Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital
June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

Maggie L. Shaw Anjali Vaidya, MD, FACC, FASE, FACP
Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Managed Care Cast logo
July 11th 2024

Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

Mary Caffrey
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Saad Z. Usmani, MD, MBA | Image credit: MSKCC
June 2nd 2025

Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS

Mary Caffrey
Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
June 2nd 2025

Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

Rose McNulty
Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo